etanercept,adalimumab
amgen,abbvie
['adalimumab', 'etanercept']
data from corevitas ra registry shows persistence for first-line monotherapy with etanercept, adalimumab and jakis no different at 12 months. 20-25% switching at 12-months. clearly more to secondary failure than anti-drug antibodies. #acr22 
Rheumatology nerd. Opinions are my own (except when wrong)